Research output per year
Research output per year
Personal profile
Expertise related to UN Sustainable Development Goals
In 2015, UN member states agreed to 17 global Sustainable Development Goals (SDGs) to end poverty, protect the planet and ensure prosperity for all. This person’s work contributes towards the following SDG(s):
Fingerprint
Dive into the research topics where Pirkko-Liisa Kellokumpu-Lehtinen is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 6 Similar Profiles
Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
Long-term effects of aromatase inhibitor withdrawal on bone mineral density in early breast cancer patients: 10-year follow-up results of the BREX study
Blomqvist, C., Vehmanen, L., Kellokumpu-Lehtinen, P. L., Huovinen, R., Ruohola, J., Penttinen, H., Sievänen, H., Nikander, R., Utriainen, M. & Saarto, T., 2024, In: Breast Cancer Research and Treatment. 206, p. 57-65Research output: Contribution to journal › Article › Scientific › peer-review
Open AccessFile -
Long-Term Outcomes of Adjuvant Trastuzumab for 9 Weeks or 1 Year for ERBB2-Positive Breast Cancer: A Secondary Analysis of the SOLD Randomized Clinical Trial
Joensuu, H., Fraser, J., Wildiers, H., Huovinen, R., Auvinen, P., Utriainen, M., Villman, K. K., Halonen, P., Granstam-Björneklett, H., Tanner, M., Sailas, L., Turpeenniemi-Hujanen, T., Yachnin, J., Huttunen, T., Neven, P., Canney, P., Harvey, V. J., Kellokumpu-Lehtinen, P. L. & Lindman, H., Aug 2024, In: Jama Network Open. 7, 8, p. e2429772Research output: Contribution to journal › Article › Scientific › peer-review
Open AccessFile -
Long-term patient-reported outcomes from monarchE: Abemaciclib plus endocrine therapy as adjuvant therapy for HR+, HER2-, node-positive, high-risk, early breast cancer
Tolaney, S. M., Guarneri, V., Seo, J. H., Cruz, J., Abreu, M. H., Takahashi, M., Barrios, C., McIntyre, K., Wei, R., Munoz, M., Antonio, B. S., Liepa, A. M., Martin, M., Johnston, S. R. D., Kellokumpu-Lehtinen, P. L. & Harbeck, N., Mar 2024, In: EUROPEAN JOURNAL OF CANCER. 199, 113555.Research output: Contribution to journal › Article › Scientific › peer-review
Open AccessFile -
Neuropilin-1 and placental growth factor as prognostic factors in metastatic breast cancer
Mäenpää, N., Tiainen, L., Hämäläinen, M., Luukkaala, T., Tanner, M., Lahdenperä, O., Vihinen, P., Karihtala, P., Kellokumpu-Lehtinen, P. L., Moilanen, E. & Jukkola, A., 2024, In: BMC Cancer. 24, 1, 331.Research output: Contribution to journal › Article › Scientific › peer-review
Open AccessFile -
PTPN9 regulates HER3 phosphorylation during trastuzumab treatment and loss of PTPN9 is a potential biomarker for trastuzumab resistance in HER2 positive breast cancer
Azad, A., Arshad, M., Generali, D., Feldinger, K., Gijsen, M., Strina, C., Cappelletti, M., Andreis, D., Leek, R., Haider, S., Kellokumpu-Lehtinen, P. L., Roxanis, I., Harris, A. L., Shaaban, A. M., Joensuu, H. & Kong, A., 2024, (E-pub ahead of print) In: Cancer Communications.Research output: Contribution to journal › Letter › Scientific
Open AccessFile
Activities
-
High baseline Tie1 predicts poor survival in metastatic breast cancer
Tiainen, L. (Contributor), Korhonen, E. (Contributor), Luukkaala, T. (Contributor), Hämäläinen, M. (Contributor), Tanner, M. (Contributor), Lahdenperä, O. (Contributor), Vihinen, P. (Contributor), Jukkola, A. (Contributor), Karihtala, P. (Contributor), Moilanen, E. (Contributor), Alitalo, K. (Contributor) & Kellokumpu-Lehtinen, P. (Contributor)
21 Mar 2018Activity: Talk or presentation › Conference presentation
-
Kilpirauhassyövän sairastaneiden potilaiden kardiovaskulaarisairastavuus ja -kuolleisuus
Huhtala, H. (Contributor), Jaatinen, P. (Contributor) & Kellokumpu-Lehtinen, P.-L. (Contributor)
23 Mar 2017Activity: Talk or presentation › Conference presentation
-
Kilpirauhassyövän sairastaneiden potilaiden kardiovaskulaarisairastavuus ja -kuolleisuus
Pajamäki, N. (Contributor), Metso, S. (Contributor), Hakala, T. (Contributor), Ebeling, T. (Contributor), Huhtala, H. (Contributor), Ryödi, E. (Contributor), Sand, J. (Contributor), Kellokumpu-Lehtinen, P.-L. (Contributor), Jukkola-Vuorinen, A. (Contributor) & Jaatinen, P. (Contributor)
22 Mar 2017Activity: Talk or presentation › Conference presentation
-
Adjuvant capesitabine in combination with docetaxel (T), epirubicin (E), and cyclophosphamide (C) in the treatment of early breast cancer (BC): 10-year survival results from the randomized FinXX trial
Joensuu, H. (Keynote speaker), Kellokumpu-Lehtinen, P.-L. (Keynote speaker), Huovinen, R. (Keynote speaker), Jukkola-Vuorinen, A. (Keynote speaker), Tanner, M. (Keynote speaker), Kokko, R. (Keynote speaker), Auvinen, P. (Keynote speaker), Lahdenperä, O. (Keynote speaker), Villman, K. (Keynote speaker), Nyandoto, P. (Keynote speaker), Nilsson, G. (Keynote speaker), Murashev, M. (Keynote speaker), Poikonen-Saksela, P. (Keynote speaker), Bono, P. (Keynote speaker), Kataja, V. (Keynote speaker) & Lindman, H. (Keynote speaker)
9 Jul 2016Activity: Talk or presentation › Invited lecture
-
A randomized phase III trial between adjuvant docetaxel and surveillance after radical prostatectomy for high risk prostate cancer : Results of SPCG12
Tammela, T. (Speaker) & Kellokumpu-Lehtinen, P.-L. (Speaker)
7 Jun 2016Activity: Talk or presentation › Conference presentation